Indolinone compounds and uses thereof
Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
1. A method for inhibiting proliferation of a cell, wherein the cell overexpresses an ETS gene or comprises an ETS fusion gene, comprising:
contacting the cell with an effective amount of a compound having a structure of Formula (Ia):
or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof,
wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of H and Cl;
wherein R 7 , R 8 , R 10 and R 11 are independently selected from the group consisting of H and halogen; and
wherein R 9 is C 3-8 cycloalkyl.
2. The method of claim 1 , wherein the ETS gene or the ETS fusion gene is selected from the group consisting of FLI1, ERG, ETV1, and ETV4.
3. The method of claim 1 , wherein the cell is a cancer cell, wherein the cancer is selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head cancer, neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer.
4. The method of claim 3 , wherein the cell is a cancer cell, wherein the cancer is selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head cancer, neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer.
5. The method of claim 1 , wherein R 9 is cyclopropyl.
6. The method of claim 1 , wherein R 1 and R 4 are Cl, and R 2 and R 3 are H.
7. The method of claim 1 , wherein the compound is selected from the group consisting of:
8. The method of claim 1 , wherein the compound is selected from the group consisting of:
9. The method of claim 1 , wherein the compound is:
10. A method of killing or inhibiting growth of a neoplastic cell, comprising:
contacting the cell with an effective amount of a compound having a structure of Formula (Ia):
or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof,
wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of H and;
wherein R 7 , R 8 , R 10 and R 11 are independently selected from the group consisting of H and halogen; and
wherein R 9 is C 3-8 cycloalkyl.
11. The method of claim 10 , wherein R 9 is cyclopropyl.
12. The method of claim 10 , wherein R 1 and R 4 are Cl, and R 2 and R 3 are H.
13. The method of claim 10 , wherein the compound is selected from the group consisting of:
14. The method of claim 1 , wherein the compound is selected from the group consisting of:
15. The method of claim 10 , wherein the compound is:
16. The method of claim 10 , wherein the cell is a cancer cell, wherein the cancer is selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head cancer, neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer.